Vitamin D Levels Are Associated With Blood Glucose and BMI in COVID-19 Patients, Predicting Disease Severity
Overview
Authors
Affiliations
Context: A high prevalence of vitamin D (VD) deficiency in COVID-19 patients has been reported and hypothesized to increase COVID-19 severity likely because of its negative impact on immune and inflammatory responses. Furthermore, clear associations between hypovitaminosis D and fat body mass excess and diabetes, factors associated with COVID-19 severity, have been widely recognized.
Objective: The aim of this study was to evaluate in COVID-19 patients the relationship between VD levels and inflammatory response, body mass index (BMI), blood glucose (GLU), and disease severity.
Methods: Patients admitted to San Raffaele-Hospital for COVID-19 were enrolled in this study, excluding those with comorbidities and therapies influencing VD metabolism. 25-Hydroxyvitamin D levels, plasma GLU levels, BMI, and inflammatory parameters were evaluated at admission.
Results: A total of 88 patients were included. Median VD level was 16.3 ng/mL and VD deficiency was found in 68.2% of patients. VD deficiency was found more frequently in male patients and in those affected by severe COVID-19. Regression analyses showed a positive correlation between VD and PaO2/FiO2 ratio, and negative correlations between VD and plasma GLU, BMI, neutrophil/lymphocyte ratio, C-reactive protein, and interleukin 6. Patients with both hypovitaminosis D and diabetes mellitus, as well those with hypovitaminosis D and overweight, were more frequently affected by a severe disease with worse inflammatory response and respiratory parameters, compared to those without or just one of these conditions.
Conclusion: We showed, for the first-time, a strict association of VD levels with blood GLU and BMI in COVID-19 patients. VD deficiency might be a novel common pathophysiological mechanism involved in the detrimental effect of hyperglycemia and adiposity on disease severity.
Morphometric vertebral fractures at hospitalization associate with Long COVID occurrence.
Di Filippo L, Doga M, Mangini F, Gifuni L, Sahagun S, Querini P J Endocrinol Invest. 2025; .
PMID: 39932650 DOI: 10.1007/s40618-025-02544-1.
Constantin L, Ungurianu A, Tarcomnicu I, Balulescu E, Margina D Germs. 2025; 14(3):232-245.
PMID: 39776957 PMC: 11703589. DOI: 10.18683/germs.2024.1435.
Modern approach to bone comorbidity in prolactinoma.
Uygur M, Menotti S, Santoro S, Giustina A Pituitary. 2024; 27(6):802-812.
PMID: 39541075 DOI: 10.1007/s11102-024-01469-x.
Vitamin D and hip protectors in osteosarcopenia: a combined hip fracture preventing approach.
Giustina A, Giustina A Rev Endocr Metab Disord. 2024; 26(1):1-18.
PMID: 39352578 PMC: 11790758. DOI: 10.1007/s11154-024-09907-8.
Gonzalez-Acedo A, Manzano-Moreno F, Garcia-Recio E, Ruiz C, De Luna-Bertos E, Costela-Ruiz V Nutrients. 2024; 16(18).
PMID: 39339670 PMC: 11434975. DOI: 10.3390/nu16183070.